【摘要】 目的探讨两种新辅助化疗方案对乳腺癌患者近期疗效及生存率的影响。方法选取2009年2月~2012年4月我院收治的63例乳腺癌患者,按照新辅助化疗方案的不同分为TE组23例和TEC组40例,其中TE组患者采用多西他赛+表柔比星方案化疗,TEC组患者则采用多西他赛+表柔比星+环磷酰胺方案化疗,对比两组患者的近期疗效及3年生存率。结果 TE组患者的总有效率为78.3%(18/23),TEC组患者的总有效率为80.0%(32/40),两组差异无统计学意义(P>0.05);3年生存率统计结果显示,TE组患者生存17例,生存率为73.9%,TEC组患者生存37例,生存率为92.5%,TEC组患者的3年生存率显著高于TE组,差异有统计学意义(P<0.05)。结论多西他赛、表柔比星、环磷酰胺的新辅助化疗方案用于乳腺癌患者的疗效确切,3年生存率明显高于多西他赛联合表柔比星方案,值得临床推广应用。更多还原

【Abstract】 Objective To explore and study the effects of two new protocols of adjuvant chemotherapy on the shortterm curative effect and survival rate of patients with breast cancer.Methods 63 patients with breast cancer who were admitted to our hospital from February 2009 to April 2012 were selected as research subjects.They were assigned to TE group of 23 patients and TEC group of 40 patients according to the different new protocols of adjuvant chemotherapy.The patients in the TE group were given the chemotherapy of docetaxel + epirubicin,and the patients in the TEC group was given the chemotherapy of doeetaxel+epirubicin+eyclophosphamide.The short-term curative effect and 3-year survival rate of the two groups were compared.Results The total effective rate in the TE group was 78.3%(18/23),and the total effective rate in the TEC group was 80.0%(32/40).There was no significant difference between the two groups of patients(P>0.05);statistical results of 3-year survival rate showed that there were 17 survived patients in the TE group,with the survival rate of 73.9%,and there were 37 survived patients in the TEC group,with the survival rate of 92.5%.The 3-year survival rate in the TEC group was significantly higher than that in the TE group,the difference was statistically significant(P<0.05).Conclusion The new protocol of adjuvant therapy of docetaxel,epirubicin and cyclophosphamide has an exact curative effect in the patients with breast cancer,and the 3-year survival rate is significantly higher than that of the protocol of docetaxel combined with epirubicin,which is worthy of clinical promotion and application.更多还原